InflaRx N.V. (IFRX): Price and Financial Metrics
IFRX Price/Volume Stats
| Current price | $1.44 | 52-week high | $4.09 |
| Prev. close | $1.46 | 52-week low | $1.14 |
| Day low | $1.38 | Volume | 89,500 |
| Day high | $1.49 | Avg. volume | 172,386 |
| 50-day MA | $1.52 | Dividend yield | N/A |
| 200-day MA | $1.53 | Market Cap | 84.79M |
IFRX Stock Price Chart Interactive Chart >
InflaRx N.V. (IFRX) Company Bio
Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.
Latest IFRX News From Around the Web
Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom FishingInflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerInflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumMulti-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
IFRX Price Returns
| 1-mo | 4.35% |
| 3-mo | -7.69% |
| 6-mo | -8.86% |
| 1-year | -62.98% |
| 3-year | -49.47% |
| 5-year | -52.32% |
| YTD | -11.66% |
| 2023 | -47.42% |
| 2022 | -34.87% |
| 2021 | -5.37% |
| 2020 | 27.02% |
| 2019 | -89.11% |
Loading social stream, please wait...